Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Imunon
Study ID
NCT02480374
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.

Key Dates

Start date
Sep 30, 2015
Status verified
Oct 2024
Primary completion
May 31, 2017
Completion
May 31, 2017

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    Carboplatin + Paclitaxel + IMNN-001

Primary Outcome Measure

DLT [ Time Frame: 4 weeks ]

Locations (4)

FacilityCityStateZIPSite coordinators
University of Alabama Birmingham Cancer CenterBirminghamAlabama35233-
Washington Univ. in St. Louis/Barnes Jewish HospitalSt LouisMissouri63110-
Stephenson Cancer CenterOklahoma CityOklahoma73104-
Medical College of Wisconsin/Froedtert HospitalMilwaukeeWisconsin53226-

Find similar trials in Birmingham, AL

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Alabama Birmingham Cancer Center· Birmingham, ALWashington Univ. in St. Louis/Barnes Jewish Hospital· St Louis, MOStephenson Cancer Center· Oklahoma City, OKMedical College of Wisconsin/Froedtert Hospital· Milwaukee, WI

Related Studies